Press "Enter" to skip to content

Possible COVID-19 Vaccine Arrives for Clinical Trials in Indonesia

  • A potential COVID-19 vaccine developed by Sinovac Biotech, a China-based biopharmaceutical company, arrived in Indonesia on Sunday.
  • Acting Foreign Ministry spokesperson Teuku Faizasyah said the possible vaccine had been sent for a clinical trial to state-owned pharmaceutical holding firm PT Bio Farma.
  • The vaccine materials sent out from China would be formulated at the facilities of Bio Farma. In Indonesia, the Phase 3 trial will include almost 1,600 participants and will be funded by Bio Farma.
  • Visit The Financial Today’s homepage for more stories.

Jakarta • A potential COVID-19 vaccine developed by Sinovac Biotech, a China-based biopharmaceutical company, arrived in Indonesia on Sunday.

Acting Foreign Ministry spokesperson Teuku Faizasyah said the possible vaccine had been sent for a clinical trial to state-owned pharmaceutical holding firm PT Bio Farma.

“The vaccine material arrived on Sunday. It has been delivered to Bio Farma,” Faizasyah said on Monday.

He said the Foreign Ministry was only facilitating the delivery from China to Indonesia, and Bio Farma had partnered with Sinovac Biotech to enable the two companies to move technology and vaccine materials.

“Our short-term strategy is to ensure access to a [COVID-19] vaccine as soon as it is ready for mass production through international cooperation,” he said. “Indonesia has also set up a national consortium as a long-term strategy to ensure we can produce a vaccine independently,” Faizasyah added.

During a press briefing on Thursday, Honesti Basyir, president of Bio Farma, said the company was ready to launch a Phase 3 clinical trial for the vaccine in Indonesia before authorities approve its widespread use. The trial is set to begin soon in cooperation with the Padjadjaran University in Bandung, West Java, as well as the research and development agency of the Health Ministry.

He added that the vaccine materials sent out from China would be formulated at the facilities of Bio Farma. In Indonesia, the Phase 3 trial will include almost 1,600 participants and will be funded by Bio Farma.

Be First to Comment

Leave a Reply

Hi, I'm Alfred Cardenas!We’re running an equity crowdfunding campaign.

This is your chance to invest and own a part of The Financial Today!